GLP-1 Weight Loss Drugs Explained: How Semaglutide, Tirzepatide, and Similar Medications Work

GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1, a hormone naturally secreted by intestinal L-cells in response to food intake. GLP-1 acts on multiple targets: it stimulates insulin secretion from the pancreas in a glucose-dependent manner, suppresses glucagon (which would otherwise raise blood sugar), slows gastric emptying (keeping food in the stomach longer and prolonging satiety), and — crucially for weight management — acts directly on the hypothalamus and other brain regions to reduce appetite and food cravings. Semaglutide and tirzepatide are the two dominant drugs in this class for weight loss as of 2025, and they are producing outcomes that have genuinely changed the landscape of obesity medicine: average reductions of 15–22% of total body weight in controlled trials, far exceeding anything previously available in the obesity pharmacotherapy toolkit.

How GLP-1 Agonists Work: The Biology

GLP-1 is an incretin — a gut-derived hormone that amplifies insulin secretion after a meal. When you eat, GLP-1 is released from intestinal cells, signals the pancreas to produce insulin proportional to the glucose load, and simultaneously suppresses glucagon. This is why GLP-1 drugs do not cause hypoglycemia in non-diabetic patients: the insulin secretion only occurs when blood glucose is elevated.

The weight loss mechanism is primarily central and peripheral appetite suppression. GLP-1 receptors in the hypothalamus, particularly in the arcuate nucleus and brainstem, regulate hunger and satiety signals. Patients taking GLP-1 agonists consistently report reduced appetite, smaller portion sizes, fewer food cravings, decreased interest in high-fat or high-sugar foods, and an earlier sense of fullness. This is not willpower — it is pharmacological re-calibration of the homeostatic and hedonic pathways that regulate food intake, both of which are dysregulated in obesity.

Gastric emptying slowing contributes to satiety as well: the stomach retains food longer, sustaining post-meal fullness and blunting the speed of glucose absorption.

Semaglutide: Ozempic vs. Wegovy

Semaglutide is a long-acting GLP-1 receptor agonist administered once weekly by subcutaneous injection. It exists under two brand names in the United States that reflect different indications and doses:

• Ozempic: FDA-approved for type 2 diabetes management. Available in 0.5 mg, 1 mg, and 2 mg weekly doses. Also has FDA approval to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
• Wegovy: FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The maintenance dose is 2.4 mg weekly, higher than the maximum diabetes dose, reached after a 16-week titration to minimize GI side effects. In the STEP 1 trial, participants lost an average of 14.9% of body weight over 68 weeks — approximately 33 pounds for a 220-pound person — compared to 2.4% with placebo.

Ozempic prescribed for weight loss in people without diabetes is off-label use, though clinically common given Wegovy's persistent supply shortages. Rybelsus is oral semaglutide (14 mg daily) approved for type 2 diabetes; evidence for weight loss is more modest compared to injectable semaglutide.

Tirzepatide: Mounjaro vs. Zepbound

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it targets both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP is another incretin with its own appetite-modulating and metabolic effects. The dual mechanism appears to produce greater weight loss than GLP-1 agonism alone.

• Mounjaro: FDA-approved for type 2 diabetes at doses of 5 mg, 10 mg, and 15 mg weekly.
• Zepbound: FDA-approved in late 2023 for chronic weight management. In the SURMOUNT-1 trial, participants with obesity (without diabetes) who received the maximum 15 mg dose lost an average of 20.9% of body weight — approximately 52 pounds in a 250-pound person — compared to 3.1% with placebo. This is among the highest weight loss seen in any pharmacotherapy trial and approaches outcomes seen with bariatric surgery in responders.

Other GLP-1 and Related Medications

Liraglutide (Saxenda) was the first GLP-1 agonist approved for weight loss (2014) at 3 mg daily via injection; it produces average weight loss of approximately 5–8% of body weight and has largely been supplanted in practice by semaglutide and tirzepatide due to the latter's superior outcomes and weekly rather than daily dosing. Exenatide and dulaglutide are GLP-1 agonists used in diabetes that have modest weight effects. Several next-generation agents targeting additional receptor combinations (GLP-1/glucagon, GLP-1/GIP/glucagon triple agonists) are in clinical trials with preliminary data suggesting even greater weight reduction.

Average Weight Loss Outcomes

To contextualize these numbers against prior options: orlistat (Xenical), the longest-available weight loss drug, produces approximately 3–5% weight loss. Phentermine-topiramate (Qsymia) produces approximately 7–9%. Naltrexone-bupropion (Contrave) approximately 4–5%. The GLP-1 class, and tirzepatide in particular, represents an order-of-magnitude improvement in pharmacological obesity treatment — the difference between losing 10 pounds and losing 50 pounds.

Not everyone responds equally. Approximately 10–15% of people taking semaglutide are "non-responders" — losing less than 5% of body weight. Predictors of better response include higher baseline BMI, absence of severe food-related anxiety or eating disorders, and consistent titration without dose interruptions due to side effects.

Side Effects

The most common side effects are gastrointestinal and dose-dependent:

• Nausea: The most frequent complaint, particularly during dose titration. Affects 40–50% of patients at some point. Usually diminishes significantly after 4–8 weeks at each dose level. Eating slowly, avoiding high-fat meals, and eating smaller portions significantly reduces nausea.
• Vomiting: Less common than nausea; approximately 20–25% of patients at some point during treatment.
• Diarrhea or constipation: Both occur; constipation becomes more common at higher doses due to reduced GI motility from gastric emptying slowing.
• Decreased appetite: The intended effect, but some patients find it difficult to maintain adequate protein and caloric intake. Protein deficiency and lean muscle loss are real clinical concerns, particularly in patients who lose weight rapidly. Adequate protein intake (at least 1.0–1.2 g/kg of ideal body weight per day) and resistance exercise during weight loss are essential to preserve lean mass.
• Pancreatitis: A rare but serious potential complication. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should not use GLP-1 agonists due to a theoretical risk identified in animal studies (though not confirmed in human data). History of pancreatitis is a relative contraindication.
• "Ozempic face": A colloquial term for the facial volume loss (fat atrophy) that occurs with rapid significant weight loss. Not a unique drug effect — any significant weight loss causes facial volume reduction. Slower, more gradual weight loss and maintaining nutrition minimize this.

Who Qualifies: BMI Criteria and Insurance

FDA approval criteria for Wegovy and Zepbound:

• BMI ≥30 (obesity), or
• BMI ≥27 (overweight) plus at least one weight-related comorbidity: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease

Insurance coverage remains highly variable. Medicare began covering anti-obesity medications for cardiovascular risk reduction following the SELECT trial results (semaglutide at Wegovy dose reduced major cardiovascular events by 20% in non-diabetic obese adults with prior cardiovascular disease), but coverage for weight loss alone varies widely by plan. Many private insurers still exclude anti-obesity medications from formularies. Cash pay costs for Wegovy and Zepbound are approximately $1,000–$1,300 per month before coupons or manufacturer savings programs. Manufacturer discount programs (the Novo Nordisk savings card for Wegovy; the Eli Lilly savings card for Zepbound) can reduce out-of-pocket cost to $25–$150 per month for commercially insured patients who qualify.

Cost and Access in Practice

Supply shortages have affected both Wegovy and Ozempic since 2022, though manufacturing has expanded significantly and availability has improved. Compounded semaglutide and tirzepatide — custom-prepared by compounding pharmacies, unregulated by the FDA — surged during the shortage period. The FDA has raised concerns about the safety and dosing accuracy of compounded versions. As branded supply normalizes, compounded versions face increasing regulatory scrutiny and are not equivalent to the FDA-approved formulations.

What Happens When You Stop

This is the most important thing patients need to understand before starting: GLP-1 agonists are chronic medications, not courses of treatment. The STEP 4 trial showed that patients who discontinued semaglutide after 20 weeks of treatment regained approximately two-thirds of their lost weight within one year. The SURMOUNT-4 trial showed similar weight regain after stopping tirzepatide. This is not failure — it reflects the biology of obesity as a chronic, relapsing disease driven by hormonal and neurological mechanisms that the medication is suppressing. Stopping the medication removes the suppression. Planning for long-term treatment from the outset is essential.

GLP-1 Drugs Are Not a Substitute for Lifestyle Change

All clinical trials of GLP-1 drugs for weight loss include intensive behavioral intervention in both the drug and placebo arms — and even patients on placebo lose 2–3% of body weight from lifestyle support alone. The combination of pharmacotherapy and lifestyle change produces better outcomes than either alone. Muscle loss during weight loss is a real risk on any intervention; resistance training and adequate protein intake are as important with GLP-1 drugs as without them. These medications are a powerful tool in a comprehensive obesity management approach, not a standalone replacement for nutrition and physical activity.

When to See a Doctor

If you have a BMI above 30, or above 27 with a weight-related health condition, and you have not been able to achieve or maintain meaningful weight loss with lifestyle modification alone, you are a candidate for pharmacotherapy and should discuss it with a physician. GLP-1 medications require a prescription and should be initiated with appropriate medical evaluation, realistic expectation-setting, and a plan for ongoing management. JourneyDoctors connects you with trained specialists from $19. Start a consultation today — no waiting room, no referral needed.

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment.

Frequently Asked Questions

Is Ozempic the same as Wegovy?

Both contain semaglutide, but they are not the same product. Ozempic is FDA-approved for type 2 diabetes at maximum doses of 2 mg weekly. Wegovy is FDA-approved for chronic weight management at a higher maximum dose of 2.4 mg weekly. Prescribing Ozempic off-label for weight loss in people without diabetes is common but the doses and titration schedules differ, and the products are not interchangeable.

Can I take GLP-1 drugs if I don't have diabetes?

Yes. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are both FDA-approved specifically for weight management in people without diabetes who meet BMI criteria. GLP-1 drugs produce insulin secretion only in response to elevated blood glucose, so hypoglycemia is not a significant concern in non-diabetic individuals taking them as prescribed.

Do GLP-1 drugs cause muscle loss?

Any significant weight loss causes some loss of lean mass alongside fat mass, and GLP-1 drugs are no exception. Studies show that approximately 25–39% of weight lost on semaglutide and tirzepatide is lean mass, which is within the range seen with other weight loss interventions including bariatric surgery. This is clinically significant — particularly in older adults where sarcopenia is already a concern. Resistance training (2–3 times per week) and adequate dietary protein (at least 1.0–1.2 g/kg of ideal body weight) are essential during treatment to preserve muscle.

How long does it take to see results?

Most patients on semaglutide or tirzepatide begin noticing reduced appetite within the first 1–2 weeks at initial doses. Meaningful weight loss (5% or more of body weight) is typically visible by weeks 8–12 of treatment. Maximum effect is usually reached at or near the maintenance dose, which takes 16–20 weeks to reach following the titration schedule. Patience during titration is important — rushing to maximum dose without allowing the GI side effects to settle leads to poor tolerability and early discontinuation.

Are GLP-1 drugs safe long-term?

Long-term cardiovascular safety data is reassuring. The SELECT trial (semaglutide 2.4 mg in non-diabetic obese adults with cardiovascular disease) demonstrated a 20% reduction in major adverse cardiovascular events over a mean follow-up of 34 months. Liraglutide has 6+ years of post-marketing safety data. Concerns about thyroid C-cell tumors (observed in rodents) have not been demonstrated in human post-marketing surveillance or clinical trial data, though the drugs remain contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2.